News & Events about Zentalis Pharmaceuticals Inc.
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) (Zentalis or the Company). The investigations concern whether certain of the Zentalis officers and directors breached their fiduciary duties to...
NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) breached their fiduciary duties to shareholders. The investigation concerns potential ...
Zentalis Pharmaceuticals (NASDAQ:ZNTL Get Rating) had its price target reduced by Wells Fargo & Company from $52.00 to $46.00 in a research note released on Monday, The Fly reports. A number of other research firms have also weighed in on ZNTL. HC Wainwright reduced their price objective on shares ...
Ticker Report
2 months ago
Zentalis Pharmaceuticals (NASDAQ:ZNTL Get Rating) had its price objective lowered by Wedbush from $51.00 to $32.00 in a report issued on Monday morning, The Fly reports. The firm currently has an outperform rating on the stock. Wedbush also issued estimates for Zentalis Pharmaceuticals’...
Brinker Capital Investments LLC grew its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL Get Rating) by 79.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,073 shares of the companys stock after buying an ...